{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:52:47Z","timestamp":1793220767204,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T00:00:00Z","timestamp":1741478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T00:00:00Z","timestamp":1741478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-92605-5","type":"journal-article","created":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T04:42:46Z","timestamp":1741495366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Adverse events reporting of edaravone: a real-world analysis from FAERS database"],"prefix":"10.1038","volume":"15","author":[{"given":"Qi","family":"Shang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junchang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maohua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,9]]},"reference":[{"key":"92605_CR1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJMra1603471","volume":"377","author":"RH Brown","year":"2017","unstructured":"Brown, R. H., Longo, D. L. & Al-Chalabi, A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 377, 162\u2013172. https:\/\/doi.org\/10.1056\/NEJMra1603471 (2017).","journal-title":"N. Engl. J. Med."},{"key":"92605_CR2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.pneurobio.2016.05.004","volume":"142","author":"M Zufir\u00eda","year":"2016","unstructured":"Zufir\u00eda, M. et al. ALS: A bucket of genes, environment, metabolism and unknown ingredients. Prog. Neurobiol. 142, 104\u2013129. https:\/\/doi.org\/10.1016\/j.pneurobio.2016.05.004 (2016).","journal-title":"Prog. Neurobiol."},{"key":"92605_CR3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.tins.2014.05.006","volume":"37","author":"S Vucic","year":"2014","unstructured":"Vucic, S., Rothstein, J. D. & Kiernan, M. C. Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies. Trends Neurosci. 37, 433\u2013442. https:\/\/doi.org\/10.1016\/j.tins.2014.05.006 (2014).","journal-title":"Trends Neurosci."},{"key":"92605_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/s1474-4422(17)30401-5","volume":"17","author":"R Chia","year":"2018","unstructured":"Chia, R., Chi\u00f2, A. & Traynor, B. J. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. 17, 94\u2013102. https:\/\/doi.org\/10.1016\/s1474-4422(17)30401-5 (2018).","journal-title":"Lancet Neurol."},{"key":"92605_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/s1474-4422(11)70015-1","volume":"10","author":"T Philips","year":"2011","unstructured":"Philips, T. & Robberecht, W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 10, 253\u2013263. https:\/\/doi.org\/10.1016\/s1474-4422(11)70015-1 (2011).","journal-title":"Lancet Neurol."},{"key":"92605_CR6","doi-asserted-by":"publisher","unstructured":"Polymenidou, M. & Cleveland, Don W. The Seeds of Neurodegeneration: Prion-like Spreading in ALS. Cell 147, 498-508, https:\/\/doi.org\/10.1016\/j.cell.2011.10.011 (2011).","DOI":"10.1016\/j.cell.2011.10.011"},{"key":"92605_CR7","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1155\/2017\/2525967","volume":"1\u201311","author":"Z Liu","year":"2017","unstructured":"Liu, Z., Zhou, T., Ziegler, A. C., Dimitrion, P. & Zuo, L. Oxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications. Oxidative Med. Cellular Longevity 1\u201311, 2017. https:\/\/doi.org\/10.1155\/2017\/2525967 (2017).","journal-title":"Oxidative Med. Cellular Longevity"},{"key":"92605_CR8","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.expneurol.2008.07.017","volume":"213","author":"H Ito","year":"2008","unstructured":"Ito, H. et al. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp. Neurol. 213, 448\u2013455. https:\/\/doi.org\/10.1016\/j.expneurol.2008.07.017 (2008).","journal-title":"Exp. Neurol."},{"key":"92605_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1179\/1351000215y.0000000025","volume":"21","author":"A Fujisawa","year":"2016","unstructured":"Fujisawa, A. & Yamamoto, Y. Edaravone, a potent free radical scavenger, reacts with peroxynitrite to produce predominantly 4-NO-edaravone. Redox Rep. 21, 98\u2013103. https:\/\/doi.org\/10.1179\/1351000215y.0000000025 (2016).","journal-title":"Redox Rep."},{"key":"92605_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/14737175.2019.1581610","volume":"19","author":"H Yoshino","year":"2019","unstructured":"Yoshino, H. Edaravone for the treatment of amyotrophic lateral sclerosis. Expert Rev. Neurother. 19, 185\u2013193. https:\/\/doi.org\/10.1080\/14737175.2019.1581610 (2019).","journal-title":"Expert Rev. Neurother."},{"key":"92605_CR11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/8755122520928495","volume":"36","author":"MA Veronin","year":"2020","unstructured":"Veronin, M. A., Schumaker, R. P. & Dixit, R. The Irony of MedWatch and the FAERS Database: An Assessment of Data Input Errors and Potential Consequences. J. Pharmacy Technol. 36, 164\u2013167. https:\/\/doi.org\/10.1177\/8755122520928495 (2020).","journal-title":"J. Pharmacy Technol."},{"key":"92605_CR12","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/apt.16601","volume":"54","author":"TA Wichelmann","year":"2021","unstructured":"Wichelmann, T. A., Abdulmujeeb, S. & Ehrenpreis, E. D. Bevacizumab and gastrointestinal perforations: a review from the FDA Adverse Event Reporting System (FAERS) database. Alimentary Pharmacol. Ther. 54, 1290\u20131297. https:\/\/doi.org\/10.1111\/apt.16601 (2021).","journal-title":"Alimentary Pharmacol. Ther."},{"key":"92605_CR13","doi-asserted-by":"publisher","unstructured":"Kim, H. S., Lee, S. & Kim, J. H. Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical Records. J. Korean Med. Sci., https:\/\/doi.org\/10.3346\/jkms.2018.33.e213, (2018).","DOI":"10.3346\/jkms.2018.33.e213"},{"key":"92605_CR14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00415-012-6665-5","volume":"260","author":"S Jong","year":"2012","unstructured":"Jong, S. et al. Endogenous female reproductive hormones and the risk of amyotrophic lateral sclerosis. J. Neurol. 260, 507\u2013512. https:\/\/doi.org\/10.1007\/s00415-012-6665-5 (2012).","journal-title":"J. Neurol."},{"key":"92605_CR15","doi-asserted-by":"publisher","unstructured":"Rooney, J. et al. C9orf72 expansion differentially affects males with spinal onset amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 88, 281.281\u2013281, https:\/\/doi.org\/10.1136\/jnnp-2016-314093 (2017).","DOI":"10.1136\/jnnp-2016-314093"},{"key":"92605_CR16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10654-018-0392-x","volume":"33","author":"B Marin","year":"2018","unstructured":"Marin, B. et al. Age-specific ALS incidence: a dose\u2013response meta-analysis. Eur. J. Epidemiol. 33, 621\u2013634. https:\/\/doi.org\/10.1007\/s10654-018-0392-x (2018).","journal-title":"Eur. J. Epidemiol."},{"key":"92605_CR17","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.15585\/mmwr.mm6746a1","volume":"67","author":"P Mehta","year":"2018","unstructured":"Mehta, P. et al. Prevalence of Amyotrophic Lateral Sclerosis \u2014 United States, 2015. MMWR. Morbidity Mortality Weekly Rep. 67, 1285\u20131289. https:\/\/doi.org\/10.15585\/mmwr.mm6746a1 (2018).","journal-title":"MMWR. Morbidity Mortality Weekly Rep."},{"key":"92605_CR18","doi-asserted-by":"publisher","first-page":"252","DOI":"10.5692\/clinicalneurol.cn-001946","volume":"64","author":"M Urushitani","year":"2024","unstructured":"Urushitani, M. et al. The clinical practice guideline for the management of amyotrophic lateral sclerosis in Japan\u2014update 2023. Rinsho Shinkeigaku 64, 252\u2013271. https:\/\/doi.org\/10.5692\/clinicalneurol.cn-001946 (2024).","journal-title":"Rinsho Shinkeigaku"},{"key":"92605_CR19","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/s0140-6736(22)01272-7","volume":"400","author":"EL Feldman","year":"2022","unstructured":"Feldman, E. L. et al. Amyotrophic lateral sclerosis. Lancet 400, 1363\u20131380. https:\/\/doi.org\/10.1016\/s0140-6736(22)01272-7 (2022).","journal-title":"Lancet"},{"key":"92605_CR20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.imr.2019.08.003","volume":"8","author":"M Cai","year":"2019","unstructured":"Cai, M. & Yang, E. J. Complementary and alternative medicine for treating amyotrophic lateral sclerosis: a narrative review. Integr. Med. Res. 8, 234\u2013239. https:\/\/doi.org\/10.1016\/j.imr.2019.08.003 (2019).","journal-title":"Integr. Med. Res."},{"key":"92605_CR21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.48691","author":"D Gupta","year":"2023","unstructured":"Gupta, D., Vagha, S., Dhingra, H. & Shirsath, H. Advances in Understanding and Treating Amyotrophic Lateral Sclerosis (ALS): A Comprehensive Review. Cureus https:\/\/doi.org\/10.7759\/cureus.48691 (2023).","journal-title":"Cureus"},{"key":"92605_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/21678421.2017.1362440","volume":"18","author":"A Kalin","year":"2017","unstructured":"Kalin, A. et al. A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies. Amyotrophic Lateral Sclerosis Frontotemporal Degeneration 18, 71\u201379. https:\/\/doi.org\/10.1080\/21678421.2017.1362440 (2017).","journal-title":"Amyotrophic Lateral Sclerosis Frontotemporal Degeneration"},{"key":"92605_CR23","doi-asserted-by":"publisher","unstructured":"Schreiber, S. et al. Brain Vascular Health in ALS Is Mediated through Motor Cortex Microvascular Integrity. Cells 12, https:\/\/doi.org\/10.3390\/cells12060957 (2023).","DOI":"10.3390\/cells12060957"},{"key":"92605_CR24","doi-asserted-by":"publisher","unstructured":"Witzel, S. et al. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis. JAMA Neurology, https:\/\/doi.org\/10.1001\/jamaneurol.2021.4893 (2022).","DOI":"10.1001\/jamaneurol.2021.4893"},{"key":"92605_CR25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40268-022-00391-6","volume":"22","author":"A Genge","year":"2022","unstructured":"Genge, A. et al. Analysis of the US Safety Data for Edaravone (Radicava\u00ae) From the Third Year After Launch. Drugs R&D 22, 205\u2013211. https:\/\/doi.org\/10.1007\/s40268-022-00391-6 (2022).","journal-title":"Drugs R&D"},{"key":"92605_CR26","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.clinthera.2020.06.016","volume":"42","author":"Y Nakamaru","year":"2020","unstructured":"Nakamaru, Y. et al. Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning. Clin. Ther. 42, 1467-1482.e1464. https:\/\/doi.org\/10.1016\/j.clinthera.2020.06.016 (2020).","journal-title":"Clin. Ther."},{"key":"92605_CR27","unstructured":"Research, C. f. D. E. a. Radicava (Edaravone) Injection. Clinical Pharmacology and Biopharmaceutics Review(s). <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209176Orig1s000ClinPharmR.pdf>."},{"key":"92605_CR28","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/21678421.2018.1517179","volume":"19","author":"J Turnbull","year":"2018","unstructured":"Turnbull, J. Is edaravone harmful? (A placebo is not a control). Amyotrophic Lateral Sclerosis Frontotemporal Degeneration 19, 477\u2013482. https:\/\/doi.org\/10.1080\/21678421.2018.1517179 (2018).","journal-title":"Amyotrophic Lateral Sclerosis Frontotemporal Degeneration"},{"key":"92605_CR29","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1136\/bmj.2.4365.308","volume":"2","author":"P Martin","year":"1944","unstructured":"Martin, P. Heparin in Intravenous Infusions, including Penicillin Therapy. BMJ 2, 308\u2013308. https:\/\/doi.org\/10.1136\/bmj.2.4365.308 (1944).","journal-title":"BMJ"},{"key":"92605_CR30","doi-asserted-by":"publisher","unstructured":"Hessov, I. & Bojsen-M\u00f8ller, M. Experimental infusion thrombophlebitis. Importance of the pH of glucose solutions. European Journal of Intensive Care Medicine 2, 97\u2013101, https:\/\/doi.org\/10.1007\/bf01886123 (1976).","DOI":"10.1007\/bf01886123"},{"key":"92605_CR31","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1093\/bja\/57.2.220","volume":"57","author":"GBH Lewis","year":"1985","unstructured":"Lewis, G. B. H. & Hecker, J. F. Infusion Thrombophlebitis. Br. J. Anaesthesia 57, 220\u2013233. https:\/\/doi.org\/10.1093\/bja\/57.2.220 (1985).","journal-title":"Br. J. Anaesthesia"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92605-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92605-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92605-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T04:42:50Z","timestamp":1741495370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92605-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,9]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["92605"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-92605-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,9]]},"assertion":[{"value":"25 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Because this study was an observational study using global open database (FAERS) with anonymized information, not involving treatment intervention or collection of human samples, informed consent was exempted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"8148"}}